- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- GLENMARK PHARMACEUTICALS LIMITED (pharmaceuticals)
- GLENMARK PHARMACEUTICALS LIMITED Financial Data
Glenmark Pharma Fact Sheet 
(GLPH)
Here is the latest financial fact sheet of Glenmark Pharma. For more details, see the Glenmark Pharma quarterly results and Glenmark Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
GLENMARK PHARMA Price History
| % ch | % | 0.7 |
| No. of shares | m | 271.28 |
| % ch week | % | -0.5 |
| % ch 1-mth | % | -11.1 |
| % ch 12-mth | % | -20.8 |
| 52 week H/L | Rs | 748.0/494.5 |
GLENMARK PHARMA Financials
| No. of Mths Year Ending |
12 Mar-13* |
12 Mar-14* |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
5-Yr Chart Click to enlarge
|
|---|
| GLENMARK PHARMA EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 551 | 612 | 879 | 1,262 | 993 | |
| Low | Rs | 301 | 464 | 752 | 672 | 729 | |
| Sales per share (Unadj.) | Rs | 185.1 | 221.4 | 244.4 | 271.1 | 325.5 | |
| Earnings per share (Unadj.) | Rs | 23.2 | 20.1 | 17.5 | 26.3 | 39.3 | |
| Diluted earnings per share | Rs | 23.2 | 20.1 | 17.5 | 27.4 | 40.9 | |
| Cash flow per share (Unadj.) | Rs | 27.9 | 28.1 | 27.1 | 34.6 | 48.7 | |
| Dividends per share (Unadj.) | Rs | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | |
| Adj. dividends per share | Rs | 2.00 | 2.00 | 2.00 | 2.08 | 2.08 | |
| Dividend yield (eoy) | % | 0.5 | 0.4 | 0.2 | 0.2 | 0.2 | |
| Book value per share (Unadj.) | Rs | 102.0 | 110.0 | 86.1 | 128.6 | 159.2 | |
| Adj. book value per share | Rs | 101.9 | 110.0 | 86.1 | 133.8 | 165.6 | |
| Shares outstanding (eoy) | m | 270.85 | 271.22 | 271.29 | 282.16 | 282.17 | |
| Bonus/Rights/Conversions | - | - | - | - | ESOP | ||
| Price / Sales ratio | x | 2.3 | 2.4 | 3.3 | 3.6 | 2.6 | |
| Avg P/E ratio | x | 18.4 | 26.7 | 46.6 | 36.7 | 21.9 | |
| P/CF ratio (eoy) | x | 15.3 | 19.1 | 30.1 | 27.9 | 17.7 | |
| Price / Book Value ratio | x | 4.2 | 4.9 | 9.5 | 7.5 | 5.4 | |
| Dividend payout | % | 8.6 | 9.9 | 11.4 | 7.6 | 5.1 | |
| Avg Mkt Cap | Rs m | 115,355 | 145,889 | 221,284 | 272,778 | 242,991 | |
| No. of employees | `000 | NA | NA | 9.5 | 10.0 | 13.0 | |
| Total wages/salary | Rs m | 7,830 | 10,262 | 12,024 | 13,782 | 16,408 | |
| Avg. sales/employee | Rs Th | NM | NM | 6,961.1 | 7,630.5 | 7,083.9 | |
| Avg. wages/employee | Rs Th | NM | NM | 1,262.5 | 1,374.8 | 1,265.4 | |
| Avg. net profit/employee | Rs Th | NM | NM | 499.0 | 741.2 | 855.1 | |
| GLENMARK PHARMA INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 50,123 | 60,052 | 66,298 | 76,496 | 91,857 | |
| Other income | Rs m | 108 | 115 | 219 | 200 | 374 | |
| Total revenues | Rs m | 50,231 | 60,167 | 66,516 | 76,696 | 92,230 | |
| Gross profit | Rs m | 10,153 | 10,908 | 10,225 | 14,372 | 20,367 | |
| Depreciation | Rs m | 1,270 | 2,168 | 2,600 | 2,343 | 2,644 | |
| Interest | Rs m | 1,600 | 1,886 | 1,902 | 1,789 | 2,373 | |
| Profit before tax | Rs m | 7,390 | 6,969 | 5,943 | 10,440 | 15,724 | |
| Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | -810 | |
| Tax | Rs m | 1,107 | 1,513 | 1,190 | 3,009 | 3,827 | |
| Profit after tax | Rs m | 6,283 | 5,456 | 4,752 | 7,430 | 11,088 | |
| Gross profit margin | % | 20.3 | 18.2 | 15.4 | 18.8 | 22.2 | |
| Effective tax rate | % | 15.0 | 21.7 | 20.0 | 28.8 | 24.3 | |
| Net profit margin | % | 12.5 | 9.1 | 7.2 | 9.7 | 12.1 | |
| GLENMARK PHARMA BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 37,268 | 47,627 | 53,199 | 59,043 | 68,746 | |
| Current liabilities | Rs m | 22,014 | 29,492 | 37,111 | 39,993 | 27,027 | |
| Net working cap to sales | % | 30.4 | 30.2 | 24.3 | 24.9 | 45.4 | |
| Current ratio | x | 1.7 | 1.6 | 1.4 | 1.5 | 2.5 | |
| Inventory Days | Days | 61 | 57 | 70 | 75 | 85 | |
| Debtors Days | Days | 119 | 131 | 138 | 119 | 96 | |
| Net fixed assets | Rs m | 27,682 | 30,357 | 17,445 | 21,416 | 24,132 | |
| Share capital | Rs m | 271 | 271 | 271 | 282 | 282 | |
| "Free" reserves | Rs m | 19,338 | 21,415 | 23,086 | 36,014 | 44,643 | |
| Net worth | Rs m | 27,630 | 29,833 | 23,357 | 36,296 | 44,925 | |
| Long term debt | Rs m | 19,203 | 24,287 | 25,744 | 24,873 | 45,363 | |
| Total assets | Rs m | 71,710 | 86,336 | 87,429 | 101,929 | 117,639 | |
| Interest coverage | x | 5.6 | 4.7 | 4.1 | 6.8 | 7.6 | |
| Debt to equity ratio | x | 0.7 | 0.8 | 1.1 | 0.7 | 1.0 | |
| Sales to assets ratio | x | 0.7 | 0.7 | 0.8 | 0.8 | 0.8 | |
| Return on assets | % | 11.0 | 8.5 | 7.6 | 9.0 | 11.4 | |
| Return on equity | % | 22.7 | 18.3 | 20.3 | 20.5 | 24.7 | |
| Return on capital | % | 19.2 | 16.4 | 16.0 | 20.0 | 19.1 | |
| Exports to sales | % | 11.9 | 11.7 | 44.8 | 43.2 | 0 | |
| Imports to sales | % | 1.7 | 1.0 | 7.1 | 7.4 | 0 | |
| Exports (fob) | Rs m | 5,957 | 7,039 | 29,720 | 33,044 | 0 | |
| Imports (cif) | Rs m | 858 | 579 | 4,680 | 5,672 | 0 | |
| Fx inflow | Rs m | 7,007 | 8,528 | 31,299 | 36,945 | 56,152 | |
| Fx outflow | Rs m | 4,135 | 3,641 | 10,856 | 61,066 | 8,084 | |
| Net fx | Rs m | 2,872 | 4,888 | 20,443 | -24,122 | 48,068 | |
| GLENMARK PHARMA CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 6,479 | 8,537 | 4,817 | 3,449 | 6,574 | |
| From Investments | Rs m | -4,641 | -3,681 | -5,400 | -8,802 | -7,124 | |
| From Financial Activity | Rs m | 1,952 | -980 | 1,992 | 6,986 | 5,432 | |
| Net Cashflow | Rs m | 2,851 | 1,896 | -311 | 934 | 1,992 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: Glenn Saldanha (MD) | COMP SEC: Sanjay Kumar Chowdhary | YEAR OF INC: 1977 | BSE CODE: 532296 | FV (Rs): 1 | DIV YIELD (%): 0.4 |
More Pharmaceuticals Company Fact Sheets: AUROBINDO PHARMA ALEMBIC PHARMA SUVEN LIFE DIVIS LABORATORIES ALKEM LABORATORIES
Compare GLENMARK PHARMA With: AUROBINDO PHARMA ALEMBIC PHARMA SUVEN LIFE DIVIS LABORATORIES ALKEM LABORATORIES
Compare GLENMARK PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends Day in Red; SBI Up 3.7%(Closing)
After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.
Views on news
Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)
Nov 7, 2017Poor show in the US, Latam and India hit profits during the quarter.
Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)
Oct 30, 2017The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)
Feb 2, 2018Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.
More Views on NewsMost Popular
My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)
May 16, 2018The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.
How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)
May 17, 2018A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.
Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)
May 17, 2018Home loans continue to grow, despite falling sales. What explains this phenomenon?
Looking Beyond the Colourful Prism of This Airline Company(Sector Info)
May 10, 2018Can Interglobe Aviation Safely Fly Out of Turbulence?
Beware of Inflated Stock Market Angels(Sector Info)
May 17, 2018The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.
More|
| |
TRACK GLENMARK PHARMA
- Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GLENMARK PHARMA
GLENMARK PHARMA - TEVA PHARMA COMPARISON
COMPARE GLENMARK PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.